CoLucid Pharmaceuticals (CLCD) versus Sanofi (SNY) Critical Review
Sanofi (NYSE: SNY) and CoLucid Pharmaceuticals (NASDAQ:CLCD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.
This table compares Sanofi and CoLucid Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Sanofi has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, CoLucid Pharmaceuticals has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.
Earnings & Valuation
This table compares Sanofi and CoLucid Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Sanofi||$42.69 billion||2.84||$12.81 billion||$3.92||12.30|
Sanofi has higher revenue and earnings than CoLucid Pharmaceuticals. CoLucid Pharmaceuticals is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.
Sanofi pays an annual dividend of $1.10 per share and has a dividend yield of 2.3%. CoLucid Pharmaceuticals does not pay a dividend. Sanofi pays out 28.1% of its earnings in the form of a dividend.
This is a summary of current ratings for Sanofi and CoLucid Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sanofi presently has a consensus price target of $53.50, suggesting a potential upside of 10.95%. CoLucid Pharmaceuticals has a consensus price target of $48.10, suggesting a potential upside of 3.37%. Given Sanofi’s higher possible upside, research analysts clearly believe Sanofi is more favorable than CoLucid Pharmaceuticals.
Institutional & Insider Ownership
9.9% of Sanofi shares are owned by institutional investors. Comparatively, 64.2% of CoLucid Pharmaceuticals shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 13.7% of CoLucid Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Sanofi beats CoLucid Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company’s vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company’s vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.
About CoLucid Pharmaceuticals
CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.